What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?

Hematological Oncology

Volumn 24, Issue 1, 2006, Pages 7-13

  Tobin, Gerard ^a   Rosén, Anders ^b   Rosenquist, Richard ^a,c  

^a UPPSALA UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Antigens; Chronic lymphocytic leukemia; Complementarity determining region; Immunoglobulin genes; Prognosis; VH gene usage; VH3 21

Indexed keywords

ANTIGEN; AUTOANTIGEN; B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; RECOMBINANT ANTIBODY;

B CELL LEUKEMIA; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENETIC VARIABILITY; HUMAN; IMMUNOGLOBULIN GENE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN MOTIF; REVIEW; VH GENE;

AMINO ACID SEQUENCE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; GENES, IMMUNOGLOBULIN; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MOLECULAR SEQUENCE DATA; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33645211013     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.760     Document Type: Review

References (66)

1. Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 1994; 8(10): 1640-1645.
2. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46(2): 219-234.
3. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48(1): 198-206.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94(6): 1848-1854.
5. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94(6): 1840-1847.
6. Maloum K, Davi F, Merle-Beral H, et al. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood 2000; 96(1): 377-379.
7. Tobin G, Thunberg U, Johnson A, et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 2002; 99(6): 2262-2264.
8. Kröber A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100(4): 1410-1416.
9. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100(4): 1177-1184.
10. Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003; 21(21): 3928-3932.
11. Tobin G, Thunberg U, Laurell A, et al. Patients with chronic lymphocytic leukemia with mutated VH genes presenting with Binet stage B or C form a subgroup with a poor outcome. Haematologica 2005; 90(4): 465-469.
12. Wiestner A, Rosenwald A, Barry TS, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003; 101(12): 4944-4951.
13. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348(18): 1764-1775.
14. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363(9403): 105-111.
15. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351(9): 893-901.
16. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL [letter]. Blood 2000; 95(7): 2455-2457.
17. Thunberg U, Johnson A, Roos G, et al. CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 2001; 97(6): 1892-1894.
18. Matrai Z, Lin K, Dennis M, et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001; 97(6): 1902-1903.
19. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001; 98(1): 181-186.
20. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115(4): 854-861.
21. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98(9): 2633-2639.
22. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194(11): 1639-1647.
23. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100(13): 4609-4614.
24. Ferrer A, Ollila J, Tobin G, et al. Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2004; 153(1): 69-72.
25. Durig J, Nuckel H, Cremer M, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17(12): 2426-2434.
26. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343(26): 1910-1916.
27. Kipps TJ, Tomhave E, Pratt LF, Duffy S, Chen PP, Carson DA. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989; 86(15): 5913-5917.
28. Schroeder HW, Jr., Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire [see comments]. Immunol Today 1994; 15(6): 288-294.
29. Johnson TA, Rassenti LZ, Kipps TJ. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997; 158(1): 235-246.
30. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997; 89(11): 4153-4160.
31. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102(8): 1515-1525.
32. Rosenquist R, Lindström A, Holmberg D, Lindh J, Roos G. V(H) gene family utilization in different B-cell lymphoma subgroups. Eur J Haematol 1999; 62(2): 123-128.
33. Tobin G, Thunberg U, Johnson A, et al. Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. Blood 2003; 101(12): 4952-4957.
34. Ghiotto F, Fais F, Valetto A, et al. Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. J Clin Invest 2004; 113(7): 1008-1016.
35. Tobin G, Thunberg U, Karlsson K, et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004; 104(9): 2879-2885.
36. Widhopf GF, II, Rassenti LZ, Toy TL, Gribben JG, Wierda WG, Kipps TJ. Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. Blood 2004; 104(8): 2499-2504.
37. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med 2004; 200(4): 519-525.
38. Cook GP, Tomlinson IM. The human immunoglobulin VH repertoire. Immunol Today 1995; 16(5): 237-242.
39. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302(5909): 575-581.
40. Alt FW, Baltimore D. Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci USA 1982; 79(13): 4118-4122.
41. Sakano H, Maki R, Kurosawa Y, Roeder W, Tonegawa S. Two types of somatic recombination are necessary for the generation of complete immunoglobulin heavy-chain genes. Nature 1980; 286(5774): 676-683.
42. Kelsoe G. The germinal center: a crucible for lymphocyte selection. Seminars in Immunology 1996; 8(3): 179-184.
43. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity 2000; 13(1): 37-45.
44. Küppers R, Klein U, Hansmann ML, Rajewsky K. Cellular origin of human B-cell lymphomas. N Engl J Med 1999; 341(20): 1520-1529.
45. Potter KN, Orchard J, Critchley E, Mockridge CI, Jose A, Stevenson FK. Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. Blood 2003; 101(8): 3082-3084.
46. Deane M, Norton JD. Preferential rearrangement of developmentally regulated immunoglobulin VH1 genes in human B-lineage leukaemias. Leukemia 1991; 5(8): 646-650.
47. Lin K, Manocha S, Harris RJ, Matrai Z, Sherrington PD, Pettitt AR. High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment. Blood 2003; 102(3): 1145-1146.
48. Matthews C, Catherwood M, Morris TC, Alexander HD. Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. Leuk Lymphoma 2004; 45(9): 1899-1904.
49. Duke VM, Gandini D, Sherrington PD, Lin K, Heelan B, Amlot P, et al. V(H) gene usage differs in germline and mutated B-cell chronic lymphocytic leukemia. Haematologica 2003; 88(11): 1259-1271.
50. Messmer BT, Albesiano E, Messmer D, Chiorazzi N. The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. Blood 2004; 103(9): 3490-3495.
51. Ghia P, Stamatopoulos K, Belessi C, et al. Geographical patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. Blood 2005; 105(4): 1678-1685.
52. Thorsélius M, Kröber A, Murray F, et al. Strikingly Homologous Immunoglobulin Gene Rearrangements and Poor Outcome in VH3-21-utilizing Chronic Lymphocytic Leukemia Independent of Geographical Origin and Mutational Blood, in press.
53. Fält S, Merup M, Tobin G, et al. Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood 2005; 106(2): 681-689.
54. Kolar GR, Capra JD. Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin. J Clin Invest 2004; 113(7): 952-954.
55. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352(8): 804-815.
56. Martin T, Duffy SF, Carson DA, Kipps TJ. Evidence for somatic selection of natural autoantibodies. J Exp Med 1992; 175(4): 983-991.
57. He X, Goronzy JJ, Zhong W, Xie C, Weyand CM. VH3-21 B cells escape from a state of tolerance in rheumatoid arthritis and secrete rheumatoid factor. Mol Med 1995; 1(7): 768-780.
58. Elagib KE, Tengner P, Levi M, et al. Immunoglobulin variable genes and epitope recognition of human monoclonal anti-Ro 52-kd in primary Sjogren's syndrome. Arthritis Rheum 1999; 42(11): 2471-2481.
59. Sasaki M, Van De Water J, Kenny TP, et al. Immunoglobulin gene usage and immunohistochemical characteristics of human monoclonal antibodies to the mitochondrial autoantigens of primary biliary cirrhosis induced in the XenoMouse. Hepatology 2001; 34(4 Pt 1): 631-637.
60. Herve M, Xu K, Ng YS, et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005; 115(6): 1636-1643.
61. Wendel-Hansen V, Sällström J, De Campos-Lima PO, et al. Epstein-Barr virus (EBV) can immortalize B-CLL cells activated by cytokines. Leukemia 1994; 8(3): 476-484.
62. +) identified in chronic lymphocytic leukemia: evidence for autoantigen-driven leukemogenesis. Leukemia & Lymphoma 2005; 46(suppl 1): S37-S38.
63. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol 2003; 5(1): 59-63.
64. Nilsson J, Söderberg O, Nilsson K, Rosén A. Thioredoxin prolongs survival of B-type chronic lymphocytic leukemia cells. Blood 2000; 95(4): 1420-1426.
65. Nilsson J, Söderberg O, Nilsson K, Rosén A. Differentiation-associated redox-regulation in human B cell lines from stem cell/pro-B to plasma cell. Immunol Lett 2004; 94(1-2): 83-89.
66. Bäckman E, Lagerdahl I, Rydberg B, Rosén A. Overexpression of the tumor survival factor thioredoxin by accessory cells in the lymph nodes of B-CLL patients. Leukemia & Lymphoma 2005; 46(Suppl. 1): S80.